Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Kodiak Sciences Inc.NASDAQ: KOD
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization remains negative
Q3 FY2026 depreciation & amortization was $0, compared with $6.54M a year earlier. Trailing-twelve-month depreciation & amortization was $19.04M. Over 3 fiscal years it compounded at +33.7% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $4.76M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 26.32M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- +31.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.32M | -1.4% |
| FY2024 | 2024-12-31 | 26.71M | +2.9% |
| FY2023 | 2023-12-31 | 25.95M | +135.9% |
| FY2022 | 2022-12-31 | 11M | +26.3% |
| FY2021 | 2021-12-31 | 8.71M | — |
Depreciation & Amortization vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.1% is the 9th highest of 10, against a peer median of +0.4%.
- Over three fiscal years its annual growth of +33.7% compares with a peer median of +20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $528.6M USD | +3.6% | +16.8% | 3.4% | |
| LTM Jun 2026 | $411M USD | -4.2% | +3.6% | 7.7% | |
| LTM Sep 2026 | $19.04M USD | -28.1% | +33.7% | — | |
| LTM Mar 2026 | $6.46M USD | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $4.63M USD | +20.3% | +27.0% | 8.9% | |
| LTM Mar 2026 | $2.47M USD | -8.6% | +70.7% | 55.3% | |
| LTM Mar 2026 | $2.45M USD | +41.2% | -1.9% | 32.1% | |
| LTM Mar 2026 | CHF 422.43K CHF | -7.4% | +20.4% | 83.8% | |
| LTM Mar 2026 | $119.64K USD | +3.7% | -17.0% | 35.9% | |
BLTEBelite Bio, Inc | LTM Sep 2026 | $117 USD | -99.9% | +32.8% | — |
| Peer median (excluding KOD) | — | +0.4% | +20.4% | 20.5% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 8.71M | 11M | 25.95M | 26.71M | 0 |
| Gross Profit | (8.71M) | (11M) | (25.95M) | (26.71M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 217.34M | 267.59M | 206.3M | 126.1M | 182.37M |
| Selling, General & Admin | 41M | 62.79M | 71.02M | 34.05M | 52.02M |
| Operating Expenses | 258.34M | 330.38M | 251.37M | 160.14M | 234.39M |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| EBITDA | (258.26M) | (322.8M) | (234.53M) | (149.5M) | (203.65M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (267.05M) | (341.38M) | (277.32M) | (186.85M) | (234.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 298K | 7.07M | 16.73M | 11.15M | 4.52M |
| Interest Expense | 22K | 18K | 13K | 0 | 0 |
| Other Income / Expenses | 61K | 7.56M | 16.83M | 10.64M | 4.42M |
| Income Before Tax | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| EPS (Diluted) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| Weighted Avg Shares | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
| Weighted Avg Shares (Diluted) | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.